1. Genome-scale metabolic network reconstruction of model animals as a platform for translational research.
- Author
-
Wang H, Robinson JL, Kocabas P, Gustafsson J, Anton M, Cholley PE, Huang S, Gobom J, Svensson T, Uhlen M, Zetterberg H, and Nielsen J
- Subjects
- Alzheimer Disease genetics, Alzheimer Disease metabolism, Animals, Caenorhabditis elegans, Drosophila melanogaster, Genome, Humans, Mice, Mice, Transgenic, Rats, Zebrafish, Alzheimer Disease pathology, Biomarkers analysis, Disease Models, Animal, Gene Regulatory Networks, Metabolic Networks and Pathways, Proteome, Transcriptome
- Abstract
Genome-scale metabolic models (GEMs) are used extensively for analysis of mechanisms underlying human diseases and metabolic malfunctions. However, the lack of comprehensive and high-quality GEMs for model organisms restricts translational utilization of omics data accumulating from the use of various disease models. Here we present a unified platform of GEMs that covers five major model animals, including Mouse1 ( Mus musculus ), Rat1 ( Rattus norvegicus ), Zebrafish1 ( Danio rerio ), Fruitfly1 ( Drosophila melanogaster ), and Worm1 ( Caenorhabditis elegans ). These GEMs represent the most comprehensive coverage of the metabolic network by considering both orthology-based pathways and species-specific reactions. All GEMs can be interactively queried via the accompanying web portal Metabolic Atlas. Specifically, through integrative analysis of Mouse1 with RNA-sequencing data from brain tissues of transgenic mice we identified a coordinated up-regulation of lysosomal GM2 ganglioside and peptide degradation pathways which appears to be a signature metabolic alteration in Alzheimer's disease (AD) mouse models with a phenotype of amyloid precursor protein overexpression. This metabolic shift was further validated with proteomics data from transgenic mice and cerebrospinal fluid samples from human patients. The elevated lysosomal enzymes thus hold potential to be used as a biomarker for early diagnosis of AD. Taken together, we foresee that this evolving open-source platform will serve as an important resource to facilitate the development of systems medicines and translational biomedical applications., Competing Interests: The authors declare no competing interest., (Copyright © 2021 the Author(s). Published by PNAS.)
- Published
- 2021
- Full Text
- View/download PDF